Research Analysts’ Recent Ratings Updates for Kalaris Therapeutics (KLRS)

Kalaris Therapeutics (NASDAQ: KLRS) has recently received a number of price target changes and ratings updates:

• 5/23/2026 – Kalaris Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/14/2026 – Kalaris Therapeutics is now covered by Wedbush. They set an “outperform” rating and a $17.00 price target on the stock.
• 5/14/2026 – Kalaris Therapeutics is now covered by Wedbush. They set an “outperform” rating and a $17.00 price target on the stock.
• 5/13/2026 – Kalaris Therapeutics had its “outperform” rating reaffirmed by Citigroup Inc..
• 5/13/2026 – Kalaris Therapeutics had its price target lowered by Citizens Jmp from $26.00 to $25.00. They now have a “market outperform” rating on the stock.
• 4/16/2026 – Kalaris Therapeutics is now covered by Morgan Stanley. They set an “overweight” rating and a $14.00 price target on the stock.

Insider Transactions at Kalaris Therapeutics

In other Kalaris Therapeutics news, Director Srinivas Akkaraju purchased 244,300 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $4.83 per share, with a total value of $1,179,969.00. Following the completion of the acquisition, the director directly owned 2,224,147 shares of the company’s stock, valued at $10,742,630.01. This trade represents a 12.34% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 68.10% of the stock is owned by company insiders.

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.